PRPOHealthcare · Diagnostics & ResearchTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Precipio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (84): Smaller than most of the companies we track.
Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Precipio, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on PRPO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Nov 2020 | Maxim Group | Initiates | Buy | — |
| 22 Nov 2019 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 60% of US stocks
Cheaper than 36% of US stocks
Cheaper than 96% of US stocks
Higher than 82% of US stocks
Higher than 72% of US stocks
Higher than 52% of US stocks
Higher than 22% of US stocks
Higher than 25% of US stocks
Higher than 37% of US stocks
Higher than 31% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRPO appears on the weeks it earns a place.
Precipio, Inc. announced it will host its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET. The call will provide a business update for the second quarter of 2026.
Why it matters — Shareholders and investors monitoring PRPO will want to listen to the call for the company's latest quarterly business performance and outlook.
Of the 1 analysts covering Precipio, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Precipio, Inc. 50 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Precipio, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (84 of 100).
No analyst covering Precipio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRPO are extrapolating price history, which says nothing about the business.
Precipio, Inc. returned +53.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Precipio Inc. is a biotechnology company focused on developing innovative diagnostic tools for the early detection and diagnosis of cancer.
The most recent item we track (GlobeNewsWire, 31 July 2026): "Precipio Announces Q2-2026 Shareholder Update Call". Precipio, Inc. announced it will host its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET. The call will provide a business update for the second quarter of 2026.
Precipio Inc. is a biotechnology company focused on developing innovative diagnostic tools for the early detection and diagnosis of cancer. Its primary function is to provide advanced oncology diagnostic services through technologies that aim to enhance the accuracy of cancer diagnoses. Precipio is known for its proprietary ICE COLD-PCR technology, which allows for the detection of low-frequency mutations efficiently, offering a cutting-edge approach in personalized medicine. The company's contributions are significant in the healthcare sector, impacting industries involved in oncology, clinical laboratories, and personalized therapy development. Headquartered in New Haven, Connecticut, Precipio serves clients that include hospitals, academic institutions, and the bio-pharmaceutical industry. By improving diagnostic processes, Precipio plays an essential role in advancing cancer research and patient treatment strategies globally, striving to improve patient outcomes through more accurate diagnostic methods.
CEO Mr. Ilan Danieli · 54 employees · United States · https://www.precipiodx.com